COMPUTATIONAL MULTI-FACTOR MODELING TO THE SIMULTANEOUS DETERMINATION OF ASSAY AND RELATED SUBSTANCES METHOD DEVELOPMENT, VALIDATION, AND IDENTIFICATION OF MAJOR DEGRADATION PRODUCT OF COVID-19 DRUG MOLNUPIRAVIR BY HPLC: A STRATEGIC RESEARCH USING AQBD
DOI:
https://doi.org/10.22159/ijap.2025v17i2.53192Keywords:
Molnupiravir, Quality by design, AQbD, Degradation, Method Validation, LOD, Mefloquine delivery system, IdentificationAbstract
Objective: In the current study, a new approach was developed for the simultaneous determination of Molnupiravir with its degradation products using RP-HPLC by following the Analytical Quality by Design (AQbD) approach, a proactive strategy for advancing pharmaceutical research.
Methods: Development was carried out by applying the two levels of fractional factorial design (25-1 with Resolution: V, four center points, and no replicates) to the five independent factors. The separation was achieved using liquid chromatography, equipped with XBridge BEH Shield (250 mm x 4.6 mm, 3.5 µm) RP18 column at 260 nm with gradient elution. A force degradation study was performed in different stressed conditions and a major degradant was identified using modern analytical techniques.
Results: The dependent factors were assessed against independent factors using the H-N plot, Pareto chart, and 3D surface plot applied through ANOVA. Major degradant obtained from stress study was identified and characterized using LC-MS, NMR, and FTIR techniques. The analytical method was found to be specific, precise (% RSD ≤ 2.0), linear (r = 0.9999) and accurate (99.2-101.4 %) with a 0.2-0.6 mg/ml range. The LOD and LOQ were 0.02 % (0.08 µg/ml, S/N ratio ≥ 3) and 0.05 % (0.2 µg/ml, S/N ratio ≥ 10, % RSD: 2.2) respectively. The analytical solutions were stable for 48 hour in the clear glassware at room temperature. The study depicts the successful development and validation of a simultaneous determination of assay and related substances by RP-HPLC using Design of Experiments (DoE) approach.
Conclusions: A Fractional Factorial Design (FFD) experiment explored the interactions of dependent with independent factors using Design Expert software, version 13.0. This AQbD-driven approach provided an in-depth understanding of chromatographic separation factors, ensuring method reliability and effectiveness for simultaneously determining the purity and impurity of Molnupiravir assisting in regulatory compliance.
Downloads
References
Fischer WA, Eron JJ, Holman W, et al. A Phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022 Jan 19;14(628):eabl7430.doi: 10.1126/scitranslmed.abl7430.
Zou R, Peng L, Shu D, et al. Antiviral efficacy and safety of molnupiravir against Omicron variant infection: a randomized controlled clinical trial. Front Pharmacol. 2022 Jun 15:13:939573. doi: 10.3389/fphar.2022.939573. eCollection 2022.
Zhou S, Hill CS, Sarkar S, et al. Beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021 Aug 2;224(3):415-9.doi: 10.1093/infdis/jiab247.
Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021 Sep;28(9):740-6.doi:10.1038/s41594-021-00651-0.
Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr. 2021 Oct 30;15(6):102329. doi: 10.1016/j.dsx.2021.102329.
Pharmaceutical Development, International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. Q8(R2);2009. https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf (Accessed: August 2009).
Quality Risk Management, International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use. Q9(R1);2009. https://database.ich.org/sites/default/files/ICH_Q9%28R1%29_Guideline_Step4_2023_0126_0.pdf(Accessed: 18 January 2023)
Pharmaceutical Quality System, International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. Q10;2008. https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf (Accessed: 4 June 2008)
Tol T, Kadam N, Raotole N, Desai A, Samanta G. A simultaneous determination of related substances by high-performance liquid chromatography in a drug product using quality by design approach. J Chromatogr A. 2016 Feb 5:1432:26-38.doi: 10.1016/j.chroma.2015.12.080.
Celia C, Marzio LD, Locatelli M, Ramundo P, D’Ambrosio F, Tartaglia A. Current Trends in Simultaneous Determination of Co-Administered. Separations. 2020 May 28;7(2):29. DOI:10.3390/separations7020029.
Marwa HH, Ayman AG, Abdalla EAH, Shaimaa GE, Heba SM. Implementation of analytical quality by design concepts for the optimization of quantitative 1H nuclear magnetic resonance (1H-qNMR) method for quantitation of novel anti-covid drugs (molnupiravir and favipiravir) in their pharmaceutical dosage forms. Microchem. j. 2024 January; volume 196, 109582. https://doi.org/10.1016/j.microc.2023.109582.
Nuli MV, Bhikshapathi D, Garige AK, Chandupatla V, Sunkara SL, Grover P. Ultra‐high‐performance liquid chromatography method development for the quantification of Molnupiravir and its process‐related impurities using Box‐Behnken experimental design. Sep sci plus. 2024 Feb 1; 7(4): e2300213. https://doi.org/10.1002/sscp.202300213.
Bhangale C, Bhandare S, Vaditake K. Eco-Friendly Analytical Quality By Design-Based Liquid Chromatographic Method For Estimation Of Molnupiravir In Bulk And Pharmaceutical Formulation. J Pharm Negat Results, 2022;13(10):4424-35. DOI: 10.47750/pnr.2022.13.S10.06.584.
Kalpana RM, Chaitanya SKP, Sareesh K. Analytical method development and validation for the estimation of molnupiravir in bulk and pharmaceutical tablet dosage form by RP-HPLC. Int J Pharm Pharm Res. 2022 Nov 30; 25(4):208-20.
Reçber T, Timur SS, Kablan SE, Yalçın F, Karabulut TC, Gürsoy RN, Eroğlu H, Kır S, Nemutlu E. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies. J Pharm Biomed Anal. 2022 May 30:214:114693. doi: 10.1016/j.jpba.2022.114693.
Kumar GR, Babu BS, Rao RR, Vardhan VM, Abbaraju VDNK. Method development and validation of specific stability indicating RP-HPLC method for molnupiravir API. J Pharm Res Int. 2021 Dec 27;33(60B):3026-35.
Analytical Procedure Development, International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use. Q14;2023. https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116_1.pdf (Accessed: 1 November 2023).
Validation Of Analytical Procedures, International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use. Q2(R2);2023. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf (Accessed: 1 November 2023)
Dhand et al. QbD approach to method development and validation of orciprenaline sulphate by HPLC. J Global Trends Pharm Sci. 2020;11(4):8634–40.
Turpin J, Luku;ay PH, Verseput R. A quality-by-design methodology for rapid LC method development-part 1. S-Matrix Corporation. 2012.
Myers R, Montgomery D, Anderson-Cook C. Response surface methodology: process and product optimization using designed experiments. 4th ed. NJ:John Wiley & Sons;2016.
Vankudre S, Shirkoli N, Shetti P. A robust ultra performance liquid chromatography method for dacarbazine quantification in nanosponge formulation: A quality by design approach. Anal Chem Lett. 2024 Aug;14(4):513-27. DOI:10.1080/22297928.2024.2378813.
Patel et al. QbD approach to HPLC method development and validation of ceftriaxone sodium. Future Journal of Pharmaceutical Sciences. 2021 Jul 13;7(1):141. https://doi.org/10.1186/s43094-021-00286-4.
Shamim et al. QbD-Engineered Development and Validation of a RP-HPLC Method for Simultaneous estimation of Rutin and Ciprofloxacin HCl in Bilosomal Nanoformulation. ACS Omega. 2023 Jun 08;8(24):21618−27.
Bhusnure et al. QbD approach for analytical method development of anti-psychotic drug. Der Pharmacia Lettre. 2015;7(12):62-70.
Singh et al. Quality By Design: A Systematic Approach for the Analytical Method Validation. J Drug Delivery Ther. 2019; 9(3-s):1006-12. https://doi.org/10.22270/jddt.v9i3-s.3114.
Kelley B, Cromwell M, Jerkins J. Integration of QbD risk assessment tools and overall risk management. Biologicals. 2016 Sept;44(5):341-51. https://doi.org/ 10.1016/j.biologicals.2016.06.001.
Dewi et al. Quality By Design: Approach to Analytical Method Validation. Sciences of pharmacy. 2022 Jun 27;1(1):33-40. DOI:10.58920/sciphar01010033.
Mondal P, Shobharani S, Ramakrishna R. Novel stability indicating validated RP-HPLC method for simultaneous quantification of Artemether and Lumefantrine in Bulk and Tablet. Curr Pharm Anal, 2014;10(4):271-78. DOI: 10.2174/1573412910666140701183927.
Mondal P, Mahender K, Padmaja B. A novel UPLC-PDA method for the simultaneous determination of lamivudine, zidovudine, and nevirapine in bulk and tablet dosage form. Anal Chem Let. 2018 Mar 15;8(1):131-38. https://doi.org/10.1080/22297928.2017.1400921.
Gupta A, Kossambe RV, Moorkoth S. Box-Behnken design assisted eco-friendly RP-HPLC-PDA method for the quantification of Paclitaxel: Application to evaluate the solubility of Paclitaxel-Cyclodextrin complex. Int J App Pharm. 2024 Aug 24;16(6):305-15. DOI: https://dx.doi.org/10.22159/ijap.2024v16i6.51690.
Kauser R, Padavala SKC, Palanivel V. Optimization of LC-MS/MS method for the simultaneous determination of Metformin and Rosiglitazone in human plasma with Box-Behnken design. Int J App Pharm. 2024 Aug 15;16(6):98-105. DOI: https://doi.org/10.22159/ijap.2024v16i6.51936.
Annadi AM, Zaharbc NM, Nour DA, Mohamed EH, Mahmoud SA, Attia MS. Development and validation of molnupiravir assessment in bulk powder and pharmaceutical formulation by the RP-HPLC-UV method. RSC Adv. 2022 Nov 12;12: 34512-9, DOI: 10.1039/D2RA05066H.
Gandu S, Gandla KS, Repudi L. New analytical method development and validation for estimation of molnupiravir in bulk and capsule dosage form by RP-HPLC method. Cell. Mol. Biomed. Rep. 2023 Dec 14;3(3):130-6. doi: 10.55705/ cmbr.2023.375093.1087.
Camlik G, Beyazaslam F, Kara E, Ulker D, Albayrak I, Degim IT. A validated high-pressure liquid chromatography (HPLC) method for molnupiravir. Med. Res. Arch. 2022 Sep 30;10(9) :1-9. https://doi.org/10.18103/mra.v10i9.3127.
Masipogu A, Dodle J, Anisetti R. Stability indicating method development and method validation for the estimation of molnupiravir in bulk and pharmaceutical dosage preparations by RP-UPLC. Indo Am. J. Pharm. Sci. 2022 Nov 03;9(10):301-9.
Bindu M, Gandla K, Vemireddy S, Samuel S, Praharsha Y. A validated stability indicating RP-HPLC method for the determination of molnupiravir in pharmaceutical dosage form. World J. Adv. Res. Rev. 2022 Jul 22;15(01): 580–90.
Deshpande M, Shaikh F, Sable V, Patil K, Holam MR, Tare H. New stability indicating RP-HPLC method for estimation of the drug molnupiravir, Int. J. Pharm. Qual. Assur. 2023 Mar 25;14(1):149-58.
Somshetwa K, Damle M. Stability indicating eco-friendly HPLC method for molnupiravir. Int. J. Sci. Res. 2022 Mar;11(3):375-8, DOI: 10.21275/SR22307172002.
Published
How to Cite
Issue
Section
Copyright (c) 2024 SANDIP KUMAR DEY, SUMANTA MONDAL
This work is licensed under a Creative Commons Attribution 4.0 International License.
